EBV VCA IgG ELISA Kit (Epstein–Barr Virus Viral-Capsid Antigen)

Full Name: EBV VCA IgG ELISA Kit (Epstein–Barr Virus Viral-Capsid Antigen)
Reactivity: Human
Sample Type: Serum, Plasma
Sensitivity: 1.29 U/ml


Epstein–Barr virus viral-capsid antigen (EBV-VCA) is responsible for the viral capsid of the EBV and the antigen itself is the target of anti-VCA antibodies. These anti-VCA antibodies play an important role in diagnosing infectious mononucleosis. The identification of high levels of anti-VCA IgM can be used to confirm acute infection, whereas high levels of anti-VCA IgG antibodies indicates prior infection.

Anti-VCA IgM is found to appear during the early stages of EBV infection and is gone between 4-6 weeks, whereas anti-VCA IgG is only present during acute phase infection and it peaks at 2-4 weeks and persists throughout the lifetime.


Human EBV VCA IgG ELISA kit is a method designed for measuring in-vitro levels of human IgG antibodies against Epstein–Barr virus viral-capsid antigen (EBV VCA IgG) in plasma or serum samples. This assay has a minimum analytical sensitivity limit of 1.29 U/ml.


All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

  • EBV VCA coated microtiter strips.
  • Enzyme Conjugate.
  • Sample Diluent.
  • TMB Substrate.
  • Calibrator B (Cut-Off Standard).
  • Calibrator D (Positive Control).
  • Calibrator C (Weak Positive Control).
  • Calibrator A (Negative Control).
  • Washing Buffer (10x).
  • Stop Solution.


The minimum detection sensitivity level of human IgG antibodies to Epstein–Barr virus viral-capsid antigen (EBV VCA IgG) using current EBV VCA IgG ELISA kit was 1.29 U/ml. The dynamic range for this assay is 1.0 – 200.0 U/ml.


– Intra-Assay-Precision: 9.4 %
– Inter-Assay-Precision: 1.6 – 14.1 %
– Inter-Lot-Precision: 4.3 – 14.0 %
– Analytical Sensitivity: 1.29 U/mL
– Recovery: 86 – 92 %
– Linearity: 80 – 98 %
– Cross-Reactivity: No cross-reactivity to Mumps, Measles or Varicella.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL.
– Clinical Specificity: 100 %
– Clinical Sensitivity: 96 %


  1. The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis. J Med Virol. (1998) 54 (2): 145-53. Weissbrich B.
  2. Seroepidemiology of EBV and interpretation of the “isolated VCA IgG” pattern. J Med Virol. (2009) 81 (2): 325-31. De Paschale M., et al.
  3. Avidity of EBV VCA specific IgG antibodies: distinction between recent primary infection, past infection and reactivation. J Virol Methods. (1995) 52 (1-2) :95-104. Gray J.J.
  4. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. J Med Virol. (2003) 70 (4): 617-23. Robertson P., et al.


Online Enquiry Form

"*" indicates required fields

Please check mark information required:


Your secretory IgA ELISA gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA assay performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA assay's from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford